Guggenheim Raises Price Target for Praxis Precision Medicines (PRAX)

Core Insights - Praxis Precision Medicines (NASDAQ:PRAX) is identified as one of the 17 biotechnology stocks with significant upside potential, with analysts projecting over 140% upside [1] - Guggenheim analyst Yatin Suneja raised the price target for PRAX from $760 to $800, maintaining a Buy rating based on the market adoption potential of ulixacaltamide in essential tremor, which supports a market opportunity exceeding $15 billion [2] - H.C. Wainwright analyst Douglas Tsao also raised the price target for PRAX from $340 to $1,245, indicating a revised upside potential of 274% [3] Product and Market Potential - Ulixacaltamide is considered transformative for Praxis, with peak sales projections ranging from $5 billion to $10 billion, while relutrigine is expected to drive significant value with peak sales reaching $6.8 billion [4] - The company focuses on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance, including epilepsy, movement disorders, and depression [5]